18-Nov-2026 08:34:51
BIOCONGeneral news
BIOCON : GETS EU MARKETING AUTHORIZATION FOR PERTUZUMAB BIOSIMILAR
• European Commission granted marketing authorization for Pebrilzo, Biocon's biosimilar pertuzumab, for HER2-positive breast cancer across multiple disease stages in the EU • First biosimilar to receive EC marketing authorization under EMA's new tailored clinical approach; follows positive CHMP opinion on September 17, 2026 • Approval follows the recent U.S. FDA approval for the same biosimilar • Pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the United States • Approved as a 420 mg concentrate for solution for infusion, indicated for neoadjuvant, adjuvant and metastatic HER2-positive breast cancer settings
Biocon Ltd
Open attachment